REDUCE-IT HF analyses show Vascepa driven serum EPA levels that suggest potential benefits in new heart failure - Amarin Corp

Amarin Corporation announced the presentation of REDUCE-IT HEART FAILURE (HF) data. The REDUCE-IT HF analyses examined the effects of Vascepa (icosapent ethyl) on the incidence of new heart failure by achieved on-treatment serum EPA levels in REDUCE-IT patients. New heart failure and new heart failure requiring hospitalization were prespecified tertiary endpoints and were not significant in the overall patient population. Post hoc analyses were conducted based on estimated average on-treatment EPA levels in patients in the icosapent ethyl group with available EPA measurements, as compared to patients in the placebo group with available EPA measurements; these analyses showed that new heart failure and new heart failure requiring hospitalization may be reduced in patients who achieve serum EPA levels higher than approximately 150 µg/mL, though this needs to be tested prospectively. As previously reported, the REDUCE-IT cardiovascular outcomes study enrolled 8,179 patients who were required to be treated with statins and other conventional therapies, and all patients had controlled low-density lipoprotein cholesterol, elevated triglyceride levels, and either established cardiovascular disease or diabetes with other cardiovascular risk factors. Data were presented at ACC.21, the American College of Cardiology’s 70th Annual Scientific Session.